# OrphanCure Full Pipeline Report: repodb_3ab2a1d014ffd529

- Drug: Cisplatin
- Disease: Non-Small Cell Lung Carcinoma
- Mode: full
- Status: completed
- Final assessment: Unlikely

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Unlikely",
      "confidence": "Low",
      "summary": "Cisplatin is a standard chemotherapy agent for non-small cell lung carcinoma (NSCLC). However, resistance to cisplatin is a significant clinical challenge. Several studies explore mechanisms of cisplatin resistance in NSCLC and strategies to overcome it, suggesting potential for repurposing efforts focused on combination therapies or overcoming resistance.",
      "evidence_counts": {
        "total_papers": 60,
        "supporting": 20,
        "contradicting": 4,
        "inconclusive": 36
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose CISPLATIN for non-small cell lung carcinoma",
      "drug": {
        "id": "CHEMBL11359",
        "name": "CISPLATIN",
        "aliases": [
          "cis-diamminedichloroplatinum(II)",
          "cis-DDP",
          "cisplatin",
          "CDDP",
          "DDP"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "EFO_0003060",
        "name": "non-small cell lung carcinoma",
        "aliases": [
          "NSCLC",
          "non-small cell lung cancer",
          "carcinoma of lung, non-small cell",
          "lung carcinoma, non-small cell",
          "non-small cell cancer of lung"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 60,
      "polarity": {
        "supports": 20,
        "contradicts": 4,
        "inconclusive": 36
      },
      "support_ratio": "20 of 60 retrieved papers support the hypothesis",
      "queries_used": 9,
      "top_papers": [
        {
          "pmid": "35346827",
          "title": "Bisdemethoxycurcumin sensitizes the response of cisplatin resistant non-small cell lung carcinoma cell lines by activating apoptosis and autophagy.",
          "year": "2022",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "32104235",
          "title": "MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1.",
          "year": "2020",
          "relevance_score": 9.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "29243778",
          "title": "Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.",
          "year": "2017",
          "relevance_score": 9.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "38587027",
          "title": "miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.",
          "year": "2024",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "32407216",
          "title": "Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.",
          "year": "2020",
          "relevance_score": 9.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "37832810",
          "title": "Huaier suppresses cisplatin resistance in non-small cell lung cancer by inhibiting the JNK/JUN/IL-8 signaling pathway.",
          "year": "2024",
          "relevance_score": 9.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "26511807",
          "title": "Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial.",
          "year": "2016",
          "relevance_score": 8.5,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "33461544",
          "title": "Hypoxia-induced Tie1 drives stemness and cisplatin resistance in non-small cell lung carcinoma cells.",
          "year": "2021",
          "relevance_score": 8.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "38329819",
          "title": "Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance.",
          "year": "2024",
          "relevance_score": 8.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "40389113",
          "title": "Heme oxygenase 1 (HO-1) is a drug target for reversing cisplatin resistance in non-small cell lung cancer.",
          "year": "2026",
          "relevance_score": 8.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Low",
      "dimensions": {
        "mechanistic_strength": "Medium",
        "literature_strength": "Medium",
        "clinical_evidence": "Low"
      },
      "quality_scorecard": {
        "overall_score": 0.725,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "2/2 claims have paper evidence"
          },
          "citation_validity": {
            "score": 0.5,
            "reason": "0 verified, 2 partial out of 2"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/2 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 1.0,
            "reason": "2/2 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "mechanistic_specificity",
          "contradiction_handling"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "ALL evidence verification failed",
        "High toxicity profile of cisplatin requires careful consideration in combination therapies.",
        "Cisplatin is already a standard treatment for NSCLC, so 'repurposing' might imply novel indications or combinations rather than initial use."
      ],
      "limitations": [
        "The provided literature focuses heavily on overcoming cisplatin resistance rather than initial repurposing for a new indication.",
        "Lack of specific mechanistic data on common targets of cisplatin itself.",
        "Limited direct clinical evidence for novel repurposing strategies beyond established treatment protocols."
      ],
      "missing_data": [
        "Direct clinical trial data on repurposing cisplatin for NSCLC beyond its established use.",
        "Detailed mechanistic data on common targets of cisplatin in NSCLC.",
        "Information on the specific efficacy of cisplatin monotherapy in various NSCLC subtypes."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Investigate combination therapies of cisplatin with agents that overcome resistance mechanisms identified in the literature (e.g., BDMC, apatinib, miR-29b-3p modulators, Huaier).",
        "Conduct preclinical studies to evaluate the efficacy of novel drug combinations in cisplatin-resistant NSCLC models.",
        "Explore the role of Tie1 and hypoxia in cisplatin resistance and potential therapeutic interventions."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 2,
      "claims": [
        {
          "claim_id": "CLM-9e3f92",
          "statement": "Cisplatin is a chemotherapy agent used in non-small cell lung carcinoma.",
          "confidence_numeric": 0.9,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "PARTIALLY_VERIFIED",
          "targets": [],
          "citation_count": 8,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-e6d82a",
          "statement": "Mechanisms of cisplatin resistance in NSCLC involve microRNAs, signaling pathways, and cellular properties like stemness.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "PARTIALLY_VERIFIED",
          "targets": [],
          "citation_count": 5,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 2,
      "entries": [
        {
          "claim_id": "CLM-9e3f92",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "00403dd5681e",
          "timestamp": "2026-06-03T14:07:27.720825+00:00",
          "paper_evidence": [
            {
              "pmid": "35346827",
              "snippet": "Here we analyzed influence of bisdemethoxycurcumin (BDMC) on phenotype and molecular mechanisms in cisplatin-sensitive NSCLC cell lines (A549 and H460) and their cisplatin-resistant counterparts.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "32104235",
              "snippet": "The results also revealed that the inhibition of miR-103a-3p in A549/cisplatin cells significantly sensitized the...",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "29243778",
              "snippet": "Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": "Quote mismatch (fuzzy check failed)"
            },
            {
              "pmid": "38587027",
              "snippet": "This investigation sought to determine the mechanism by which miR-29b-3p inhibited the advancement of NSCLC and mitigated resistance to cisplatin.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "32407216",
              "snippet": "To evaluate the efficacy of pemetrexed plus cisplatin versus vinorelbine plus cisplatin as postoperative adjuvant chemotherapy in patients with pathologic stage II-IIIA nonsquamous non-small-cell lung",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "37832810",
              "snippet": "Huaier suppresses cisplatin resistance in non-small cell lung cancer by inhibiting the JNK/JUN/IL-8 signaling pathway.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": "Quote mismatch (fuzzy check failed)"
            },
            {
              "pmid": "26511807",
              "snippet": "We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "33461544",
              "snippet": "Hypoxia-induced Tie1 drives stemness and cisplatin resistance in non-small cell lung carcinoma cells.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": "Quote mismatch (fuzzy check failed)"
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 9
        },
        {
          "claim_id": "CLM-e6d82a",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "00403dd5681e",
          "timestamp": "2026-06-03T14:07:27.720825+00:00",
          "paper_evidence": [
            {
              "pmid": "32104235",
              "snippet": "In the present study, it was revealed that there were increased expression levels of miR-103a-3p in both NSCLC cell lines and human NSCLC samples that exhibited resistance to cisplatin.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "29243778",
              "snippet": "The changes in apoptotic proteins, multidrug resistance protein 1 (MDR1) and extracellular signal-regulated kinase (ERK) signaling pathway proteins in each group after treatment were detected by Weste",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "38587027",
              "snippet": "Non-small cell lung carcinoma (NSCLC) is a common type of lung cancer. Prior investigations have elucidated the pivotal role of miR-29b-3p in restraining tumor growth and metastasis.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "37832810",
              "snippet": "Huaier suppresses cisplatin resistance in non-small cell lung cancer by inhibiting the JNK/JUN/IL-8 signaling pathway.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": "Quote mismatch (fuzzy check failed)"
            },
            {
              "pmid": "33461544",
              "snippet": "Tie1 is upregulated in hypoxia and is believed to counteract the effectiveness of platinum agents by promoting the stemness properties in cells.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 9
        }
      ]
    }
  },
  "metadata": {
    "run_id": "00403dd5681e",
    "created_at": "2026-06-03T14:07:08.095727+00:00",
    "drug": "CISPLATIN",
    "disease": "non-small cell lung carcinoma",
    "total_claims": 2,
    "quality_score": 0.725,
    "reruns": 0
  }
}
```
